‘The success of the current booster campaign is critical for future years, and it’s not going that wellModerna earnings on Thursday offered a preview into the future of Covid-19 vaccine sales, and so far it doesn’t look pretty.
The vaccine maker said it’s signed advanced purchase agreements worth $4.5bn to $5.5bn for 2023, including up to $3bn of deferred deliveries from this year. Shares of Moderna fell 4.6% at the New York market open. Pfizer fell 1.7%, and American depositary receipts of its German partner BioNTech dropped 2.8%.Supply was limited in the US this autumn when one of Moderna’s contract manufacturing facilities came under scrutiny from US regulators.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: